NCT06110572View on ClinicalTrials.gov

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Extensive Stage Lung Small Cell CarcinomaStage IV Lung Cancer
Interventions
DRUG

Carboplatin

Given by IV

BIOLOGICAL

Atezolizumab

Given by IV

DRUG

Etoposide

Given by IV

RADIATION

Total Body Irradiation

Undergo Total Body Irradiation

RADIATION

Hypofractionated Radiation Therapy

Undergo Hypofractionated Radiation Therapy

PROCEDURE

Magnetic Resonance Imaging

Undergo Magnetic Resonance Imaging

Trial Locations (1)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT06110572 - Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation | Biotech Hunter | Biotech Hunter